 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Apr 22 Calls Today's Calls |
| Call Details | |||
| BioMimetic Therapeutics Conference Call to Address Written Communication from FDA Confirming Status of Ongoing Pivotal Trial for GEM OS1 Tue, Apr 22, 2008, 8:30 am Eastern
| |||
| About BioMimetic Therapeutics (NasdaqGM:BMTI) | Other Calls | ||
| BioMimetic Therapeutics, Inc. engages in the development and commercialization of bio-active drug-device combination products primarily used for bone and tissue regeneration for the healing of musculoskeletal injuries and diseases, including orthopedic, spine, and sports injury applications. Its lead product candidates, GEM OS1 (bone graft) and GEM OS2 (injectable bone graft), use recombinant human Platelet-Derived Growth Factor (rhPDGF-BB), a naturally occurring wound healing stimulator in the body to start the tissue regeneration process. The company’s product candidates, which also incorporate rhPDGF-BB in combination with a bone matrix, are targeted to be used in the open (surgical) treatment of fractures and fusions, the closed (non surgical) treatment of fractures, and the stimulation of bone formation at sites of risk for fracture, such as the spine in individuals with osteoporosis. The company also develops GEM OS2 for local bone augmentation for osteoporosis, as well as for prophylactic vertebral compression fracture. Its other product candidates include GEM C that is used for cartilage repair; and GEM LT for ligament and tendon repair. The company was founded in 1999. It was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in 2005. The company is headquartered in Franklin, Tennessee. | |||
More Info: | |||
